Transplant Rejection

Immunology

22 drugs in development·6 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
graftassurecore	Insight Molecular Diagnostics Inc. (IMDX)

Phase 3(4)

Phase 2(6)

Drug	Company
antithymocyte globulin	Sanofi (SNY)
clazakizumab	ALDER BIOPHARMACEUTICALS INC (ALDR)
intravenous immunoglobulin	Sanofi (SNYNF)
intravenous immunoglobulin	Sanofi (SNY)
mycophenolate	Sanofi (SNY)
vib4920	Viela Bio, Inc. (VIE)

Phase 1(2)

Drug	Company
bivv020	Sanofi (SNY)
bivv020	Sanofi (SNYNF)

Phase 1/Phase 2(1)

Drug	Company
at-1501	Eledon Pharmaceuticals, Inc. (ELDN)

Phase 2/Phase 3(5)

Drug	Company
antithymocyte globulin	Sanofi (SNY)
mycophenolate	Sanofi (SNY)
mycophenolate mofetil	Sanofi (SNY)
rabbit anti-thymocyte globulin	Sanofi (SNY)
rabbit anti-thymocyte globulin	Sanofi (SNYNF)

Phase 4(3)

BioSniper tracks 22 drugs in development for Transplant Rejection across 6 companies.

There are 1 clinical trial targeting Transplant Rejection tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.